The referral of adolescents with cancer to a pediatric oncology center diminishes greatly with age, and is moderately influenced by diagnosis and minimally by distance from center. Further study should investigate reasons for referral patterns, and impact on outcomes.

This report describes the occupant evacuation of World Trade Center (WTC) 1 and WTC 2 on September 11. 2001. Multiple sources of information were collected and analyzed: over 1,000 new interviews with survivors (including 803 telephone interviews, 225 face-to-face interviews, and 5 focus groups); over 700 published interviews; 9-1-1 emergency calls; transcripts of emergency communications, historical building design drawings, memoranda, and calculations; formal complaints filed with the Occupational Safety and Health Administration; and other relevant materials.The egress system, including stairwells and elevators, was described and compared to requirement of both contemporary and current code requirements. This report documents the emergency procedures, both as they were designed to be implemented, as well as how they were actually implemented on September 11. 2001.The population in WTC 1 and WTC 2 on September 11, 2001, at 8:46:30 a.m. was enumerated and described, where the characteristics of the population were relevant to the subsequent evacuation, including training, experience, mobility status, among others. The progress of the evacuation of both towers was described in a quasi-chronological manner from 8:46:30 a.m. when WTC 1 was attacked, until 10:28:22 a.m.. when WTC 1 collapsed.Causal models were built to explore the sources of evacuation initiation delay (why people did not immediately start to leave the building) as well as normalized stairwell evacuation time (how long the average occupant spent in the stairu'ells per floor). Issues identified as contributing to either speeding or aiding the evacuation process were explored. Egress simulations provided context for estimating how long WTC 1 and WTC 2 would have taken to evacuate with different populations, using different models, and subject to different damage to the building.

Background-Imatinib is a highly effective treatment for chronic myeloid leukemia (CML) that was approved by the Food and Drug Administration in 2001, and thereafter rapidly became front line therapy. This study characterized the prevailing chronic myeloid leukemia therapies in the United States and assessed the impact of imatinib on chronic myeloid leukemia survival and mortality rates in the general population.